What is HC Wainwright’s Estimate for Evolus FY2025 Earnings?

Evolus, Inc. (NASDAQ:EOLS) – Equities research analysts at HC Wainwright decreased their FY2025 EPS estimates for Evolus in a research note issued on Thursday, April 10th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.28) for the year, down from their prior estimate of ($0.23). HC Wainwright currently has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.61) per share.

Other research analysts have also issued research reports about the company. Barclays raised their target price on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research note on Wednesday, April 9th.

Evolus Trading Up 7.7 %

EOLS opened at $10.27 on Monday. The firm has a market capitalization of $653.04 million, a PE ratio of -11.29 and a beta of 0.97. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. Evolus has a fifty-two week low of $8.67 and a fifty-two week high of $17.82. The company’s 50-day moving average is $12.85 and its 200 day moving average is $13.27.

Insider Transactions at Evolus

In other Evolus news, insider David Moatazedi sold 6,251 shares of the business’s stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total value of $77,512.40. Following the transaction, the insider now owns 508,619 shares of the company’s stock, valued at approximately $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rui Avelar sold 27,904 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the transaction, the insider now owns 362,467 shares of the company’s stock, valued at $4,806,312.42. This trade represents a 7.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 60,575 shares of company stock worth $794,369 in the last 90 days. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EOLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Evolus by 3.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,451 shares of the company’s stock worth $347,000 after purchasing an additional 1,094 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Evolus by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock worth $148,000 after buying an additional 1,291 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Evolus by 2.2% in the fourth quarter. Rhumbline Advisers now owns 80,149 shares of the company’s stock valued at $885,000 after buying an additional 1,762 shares during the period. Tradition Wealth Management LLC raised its stake in shares of Evolus by 18.2% in the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company’s stock valued at $144,000 after buying an additional 2,000 shares during the period. Finally, MetLife Investment Management LLC lifted its position in shares of Evolus by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 34,272 shares of the company’s stock valued at $378,000 after buying an additional 2,044 shares during the last quarter. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.